Arcus Biosciences (RCUS) closed at $18.19 on October 30, 2026, down 2.3% from the previous close, on volume of 1,737,792 shares (30-day average 2,158,278).
Data as of October 30, 2026.
30-Oct-2026
Arcus Biosciences Announces New Employment Inducement Grants
Business Wire (Mon, 26-Oct 4:35 PM ET)
Arcus Biosciences prices 14.29M-share offering at $17.50, with a 30-day option for 2.14M more
Market Chameleon (Thu, 22-Oct 3:36 AM ET)
Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock
Business Wire (Wed, 21-Oct 10:53 PM ET)
Kuehn Law Encourages Investors of Arcus Biosciences, Inc. to Contact Law Firm
PRNewswire (Wed, 21-Oct 4:26 PM ET)
Arcus Biosciences Announces Commencement of Public Offering of Common Stock
Business Wire (Wed, 21-Oct 4:22 PM ET)
Market Chameleon (Tue, 20-Oct 6:26 AM ET)
Market Chameleon (Tue, 20-Oct 4:43 AM ET)
Business Wire (Tue, 20-Oct 8:30 AM ET)
Business Wire (Tue, 22-Sep 8:30 AM ET)
Arcus Biosciences to Participate in Three Upcoming Investor Conferences
Business Wire (Wed, 26-Aug 4:05 PM ET)
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
Arcus Biosciences trades on the NYSE stock market under the symbol RCUS.
As of October 30, 2026, RCUS stock price declined to $18.19 with 1,737,792 million shares trading.
RCUS has a beta of 1.24, meaning it tends to be more sensitive to market movements. RCUS has a correlation of 0.07 to the broad based SPY ETF.
RCUS has a market cap of $2.29 billion. This is considered a Mid Cap stock.
Last quarter Arcus Biosciences reported $41 million in Revenue and -$.72 earnings per share. This beat revenue expectation by $19 million and exceeded earnings estimates by $.13.
In the last 3 years, RCUS traded as high as $31.74 and as low as $6.50.
The top ETF exchange traded funds that RCUS belongs to (by Net Assets): IJR, VTI, IWM, XBI, VXF.
RCUS has underperformed the market in the last year with a price return of -9.9% while the SPY ETF gained +12.3%. RCUS has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -35.6% and -17.8%, respectively, while the SPY returned +2.1% and -1.0%, respectively.
RCUS support price is $17.78 and resistance is $19.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RCUS shares will trade within this expected range on the day.
